The U.S. FDA has approved a new indication for Symbyax (olanzapine and fluoxetine HCl capsules), Eli Lilly and Company announced today. Symbyax is now the first drug approved by the FDA for the acute treatment of treatment-resistant depression (TRD).
The details can be read here.
No comments:
Post a Comment